Early efficacy and safety data with fixed‐dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency

Tada, Yayoi; Iversen, Lars; Koo, John

doi:10.1111/jdv.17027

Cited by 10 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While Cal/BD foam is one of the staple treatments for cutaneous psoriasis, 48 only one RCT has investigated this product for PND, reporting a reduction in NAPSI of 44% after 12 weeks of daily application. 4 The notably higher efficacy rates in our study after 24 weeks of treatment (−76% N‐NAIL, −68% NAPSI) with comparable safety profile and improvement in PROMs indicate a favorable risk–benefit ratio for prolonged treatment with Cal/BD foam.…”

Section: Discussionmentioning

confidence: 99%

Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease—A hybrid trial using a smartphone application, optical coherence tomography, andpatient‐reportedoutcome measures

Ortner

Mandel

Skak

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

There is a lack of efficacious topical treatments for patients suffering from psoriatic nail disease (PND). We investigated the efficacy of Calcipotriol-Betamethasone Dipropionate (Cal/BD) foam with and without ablative fractional laser (AFL) in patients with PND. A total of 144 nails from 11 patients were treated in a 24-week long, open-label, randomized, intra-patient controlled proof-of-concept hybrid trial.In addition to daily Cal/BD foam application, half of each patient's psoriatic nails were randomized to receive optical coherence tomography (OCT)-guided AFL treatment at baseline, 6-, and 12-week follow-ups. In-clinic assessment (N-NAIL), patientreported outcomes (PROMs), and drug consumption were supplemented by remote evaluation of 15 subclinical OCT features, smartphone app-based safety monitoring, and photo-based assessment (NAPSI). After 24 weeks of Cal/BD foam treatment, patients achieved a significant improvement (p < 0.001) in both clinical (N-NAIL À76%, NAPSI À68%) and subclinical (OCT À43%) PND severity as well as a 71% reduction in PROMs. AFL-assisted Cal/BD treatment led to higher clinical (N-NAIL À85%, NAPSI À78%) and OCT-assessed (À46%) reduction of PND signs than Cal/BD alone (N-NAIL À66%, NAPSI À58%, OCT À37%), but did not reach statistical significance. Smartphone app images documented adverse events and mild local skin reactions, particularly erythema (75%), laser-induced swelling (28%), and crusting (27%). This hybrid trial demonstrated a reduction in clinical NAPSI and N-NAIL scores, subclinical OCT features, and PROMs, suggesting that Cal/BD foam is a safe and efficacious treatment for PND. Larger trials are warranted to prove the clinical benefit of AFL pretreatment as a Cal/BD delivery enhancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease—A hybrid trial using a smartphone application, optical coherence tomography, andpatient‐reportedoutcome measures

Ortner

Mandel

Skak

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…It was shown that the Cal/BD foam, as compared to gel or ointment, revealed higher skin penetration, better cosmetic qualities, and higher efficacy. 11 On top of that, foam did not increase the risk of side effects. 5 Factors with a positive effect on adherence include also the good patient-doctor relation, patient education, follow-up visits after treatment completion and patient participation in therapeutic decisions.…”

Section: Medications Used In Long-term Topical Therapy Of Psoriasismentioning

confidence: 97%

“…The most recent drug forms are foams. It was shown that the Cal/BD foam, as compared to gel or ointment, revealed higher skin penetration, better cosmetic qualities, and higher efficacy 11 . On top of that, foam did not increase the risk of side effects 5 .…”

Section: Medications Used In Long‐term Topical Therapy Of Psoriasismentioning

confidence: 99%

Proactive therapy: New perspectives for long‐term topical treatment of psoriasis

Lis‐Święty

Frątczak

2022

Dermatologic Therapy

View full text Add to dashboard Cite

Mild to moderate psoriasis is most often treated with topical therapy. The article reviews literature on topical treatments that have been assessed in clinical trials and real‐life studies lasting at least 12 months. Calcipotriol/bethamethasone dipropionate foam in maintenance treatment following the induction phase can improve efficacy and safety of topical therapy in psoriatic patients. Introduction of new topical nonsteroidal drugs and the wider use of proactive therapy seem to be crucial to achieve satisfactory long‐term outcomes in psoriasis.

show abstract

“…16 Propellants contained in the foam formulation evaporate rapidly and lead to the formation of a thin supersaturated layer on the skin increasing the penetration and the bioavailability of active ingredients Cal/BD. 17,18 In addition to data showing the superiority of Cal/BD foam over its individual components and Cal/BD ointment and gel formulations, the early efficacy of Cal/BD foam was demonstrated in the treatment of psoriasis flare-ups.…”

Section: Short Term Efficacymentioning

confidence: 99%

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination

Jalili¹,

Bewley²,

Sticherling³

et al. 2022

CCID

View full text Add to dashboard Cite

Psoriasis is a well-known chronic disease characterized by the development of erythematous, indurated, scaly, pruritic plaques on the skin with cycles of remission and symptom flare-ups. The management of patients with chronic plaque psoriasis has been more challenging since the Covid-19 pandemic as health care professionals have had to adapt to remote consultations for some patients, and patients have had to adapt to the changing health landscape. The rapid resolution of psoriasis symptoms especially those with a substantial impact on quality of life can improve patient satisfaction and adherence, making it an important factor in successful treatment. Cal/BD foam contributes to improved patient adherence and treatment outcome through its rapid action and superior efficacy versus Cal or BD monotherapy, Cal/BD ointment and gel and clobetasol cream in the short-term flare treatment of psoriasis. Moreover, the benefits of proactive long-term management of psoriasis compared to reactive management and its favourable safety profile are higher efficacy and a better health-related quality of life. Cal/BD foam should be considered an effective topical treatment for short-term flare treatment and long-term control of adult psoriatic patients.

show abstract

Early efficacy and safety data with fixed‐dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency

Cited by 10 publications

References 19 publications

Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease—A hybrid trial using a smartphone application, optical coherence tomography, andpatient‐reportedoutcome measures

Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease—A hybrid trial using a smartphone application, optical coherence tomography, andpatient‐reportedoutcome measures

Proactive therapy: New perspectives for long‐term topical treatment of psoriasis

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination

Contact Info

Product

Resources

About